Mycoplasma genitalium Mycoplasma genitalium, Nitroimidazole, Tinidazole, 23S-rRNA, parC, gyrA, Urithritis, Proctitis, Cervicitis, Sexually transmitted infections,
Conditions
Interventions
Oral administration of tinidazole 2,000mg for 3 days and doxycycline 200mg for 7 days will be carried out for the participants who tested positive for Mycoplasma genitalium.
Sponsors
Ando Naokatsu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Individuals who were adults over 18 years old at the time of consent. 2. Individuals who tested positive for Mycoplasma genitalium in urine samples, vaginal swabs, or anal swabs. 3. Individuals who obtained written consent for participation in the study. 4. Individuals confirmed to have resistance to macrolides and quinolones, or those who are thought to be at high risk based on epidemiological information (such as a history of treatment failure with sitafloxacin and moxifloxacin, MSM).
Exclusion criteria
Exclusion criteria: 1. Individuals with allergies to the treatment drugs. 2. Pregnant or breastfeeding individuals. 3. Individuals who cannot abstain from alcohol during treatment 4. Anyone else deemed inappropriate for study participation by the primary researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment Success Rate The definition of treatment success is confirmed by a negative result in the nucleic acid amplification test during the cure confirmation examination. | — |
Secondary
| Measure | Time frame |
|---|---|
| The change of bacterial load before and after treatment.New resistance mutation detection rate A 'new resistance mutation detection' is defined as the occurrence of a resistant mutation in the post-treatment resistance test, which was not present in the resistance test at the time of registration. The rate of adverse events. | — |
Contacts
Public ContactAndo Naokatsu
National Center for Global Health and Medicine, Japan Institute for Health Security
Outcome results
None listed